



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 327/32, C07D 333/24, 213/56, 295/14, 213/83, 333/38, C07C 323/53, C07D 213/75, 333/20, 333/36, 211/34, 211/96, A61K 31/16, 31/625, 31/44, 31/38	A1	(11) International Publication Number: WO 98/42662
		(43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/EP98/01584 (22) International Filing Date: 18 March 1998 (18.03.98) (30) Priority Data: 60/039,845 20 March 1997 (20.03.97) US (71) Applicant (for all designated States except AT): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT). (72) Inventor: FINK, Cynthia, Anne; 1 Kensington Court, Lebanon, NJ 08833 (US). (74) Agent: BECKER, Konrad; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CERTAIN CYCLIC THIO SUBSTITUTED ACYLAMINOACID AMIDE DERIVATIVES

(57) Abstract

Disclosed are compounds of formula (I), wherein R, R₁, R₂, R₃, R₄, A and n are as defined; pharmaceutically acceptable salts thereof; disulfides corresponding to said compounds of formula (I) wherein R₄ is hydrogen; methods for preparation thereof; pharmaceutical compositions comprising said compounds; and a method of inhibiting TNF-alpha and matrix-degrading metalloproteinase

activity and of treating TNF-alpha and matrix metalloproteinase dependent diseases or conditions, e.g. inflammatory conditions, osteoarthritis, rheumatoid arthritis and tumours, in mammals using such compounds.

